The new Avigabine herbal medicine is due to arrive on November 6, 2018, and will be available for a suggested retail price of $49.99.
This is the first time Avicennamal has been available at retail.
The product is not currently being sold in India.
The first batch of Avigablene is due in October.
The company said it will be delivered via courier on November 8, which means the product will not be available in India until then.
Avigabiene is also being produced in the UK, China, and Australia.
The new Avigenas will be the first herb medicine made by Avicenas, which is a global company based in Bangalore.
Avigenes aim to create an affordable herbal treatment for the Indian diaspora, which has seen significant economic growth and healthcare costs increase dramatically over the last few years.
“Avigabline is the product of collaboration between Avicena and Avigena and it is designed to be a safe and effective way to treat skin, skin conditions, and allergies,” said Avigenis co-founder Dr. K.S. Raja.
“We are confident in the product’s safety and efficacy and we expect it to provide significant benefits for patients.”
The product is the brainchild of Dr. Rajan Nair, who has worked at the Indian Institute of Medical Sciences (IIMS), Bombay, for over 30 years.
In 2014, Dr. Nair was awarded a National Prize in Biotechnology for his discovery of a novel antibiotic-resistant bacterium, known as Helicobacter pylori, that causes a range of chronic diseases including Crohn’s disease.
Nair is now the director of research at Avigenic.
He was named chairman of Avigenin, the company’s Indian unit, in 2018.
The team hopes to reach the market in India in 2020.
“This is the start of a new chapter for us and our team, which we have spent the last decade developing and are working very hard to deliver this medicine,” said Dr. B.M. Gopalakrishnan, Avigenics managing director.
“The Avigenase is a breakthrough in medicine and it has the potential to revolutionize our industry and the Indian healthcare system.”
The company has raised $2.3 million in venture capital in the last three years, including $1 million from Sequoia Capital and $1.3 from Kalaari Capital.